Robert Spiegel has over 30 years of R&D and operational experience in biopharmaceuticals, including large pharmaceutical and biotechnology companies and academic startups as well as serving as an advisor to venture capital and private equity funds.
After completing specialty training in Medical Oncology at the National Cancer Institute, NIH, Dr. Spiegel was an Assistant Professor and Director of the Developmental Therapeutics Program at New York University Medical Center and then spent 26 years at Schering-Plough (now Merck & Co.), which he joined as the first Director for Oncology Clinical Research. He then held a series of senior executive positions, including Senior Vice President for Worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he led teams that took numerous drug candidates through clinical development, was involved with over 30 New Drug Application approvals by the U.S. FDA, participated in multiple due diligence reviews and in-licensing decisions, re-engineered pharmacovigilance and risk management areas and built a quality system for all research operations.
Dr. Spiegel is a consultant to the biotech industry and has served on the Scientific Advisory Board and Board of Directors of multiple biotech companies. He also serves as an Adjunct Associate Professor at Weill Cornell Medical College. He received his B.A. from Yale University and his M.D. from the University of Pennsylvania.